TORONTO, April 19 /CNW/ - Spectral today announces a presentation
documenting the efficacy of its proprietary RapidWN West Nile Virus IgM Test
("RAPIDWN(TM)"). This presentation is being made at the 39th Annual Oak Ridge
Conference, entitled "Harnessing New Technology for Clinical Diagnostics".
The presentation outlines performance characteristics, as well as the
safety and effectiveness, of the assay. Included in the data are results from
studies at the National Microbiology Laboratory in Winnipeg, where Spectral's
assay was found to correlate with the gold standard test, the Plaque Reduction
and Neutralization (PRNT) assay, and 100 % of the time in acute cases of West
Nile infection. The PRNT assay takes weeks to perform and requires specialized
technicians and equipment. Spectral's assay gives results in less than thirty
minutes and requires no special equipment or training.
"Dr. Nisar Shaikh, Vice President of Scientific Affairs at Spectral will
be presenting this important data on the usefulness of our assay at this
prestigious meeting," stated Dr. Paul Walker, President and CEO of Spectral.
"Our test has been shown to be very effective in identifying patients with
West Nile infection at an early stage, when therapeutic interventions can be
used to potentially alter the incidence of adverse outcomes," he continued.
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products include Spectral's FDA approved rapid diagnostic for West
Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis
(EAA(TM)) as well as a range of other biological reagents. Spectral's common
shares are listed on The Toronto Stock Exchange under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
For further information:
For further information: Spectral Diagnostics Inc., Dr. Paul Walker,
Chief Executive Officer, (416) 626-3233